睿知中国医院研究地图
候选清单

正在招募肝细胞癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 7 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically/cytologically confirmed hepatocellular carcinoma (HCC), Barcelona Clinic Liver Cancer (BCLC) Stage C or Stage B not amenable to curative surgery and/or locoregional therapy.

    入选标准第 4 条

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with no deterioration within 2 weeks prior to first study drug administration.

    入选标准第 7 条

    Prior locoregional therapy for hepatocellular carcinoma within 4 weeks before first dose administration.

    排除标准第 6 条

    Toxicities from prior therapy that have not resolved to Grade 0 or 1 before first dose of study treatment.

    排除标准第 10 条

  4. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and modified RECIST (mRECIST).

    入选标准第 5 条

  5. Negative serum pregnancy test within 7 days prior to first dose (women of childbearing potential). Pregnant or lactating women are not eligible for this study.

    入选标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;化验:血常规、肝肾功能;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07479485,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Able to understand and provide written informed consent, and comply with the requirements specified in the protocol.
  2. Life expectancy ≥ 3 months.
  3. Must provide tumor tissue specimens for GPC3 testing.
  4. Histologically/cytologically confirmed hepatocellular carcinoma (HCC), Barcelona Clinic Liver Cancer (BCLC) Stage C or Stage B not amenable to curative surgery and/or locoregional therapy.
  5. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and modified RECIST (mRECIST).
  6. No prior systemic antineoplastic therapy for unresectable HCC before first dose administration.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with no deterioration within 2 weeks prior to first study drug administration.
  8. Adequate organ function as specified.
  9. Negative serum pregnancy test within 7 days prior to first dose (women of childbearing potential). Pregnant or lactating women are not eligible for this study.
  10. Women of childbearing potential and male patients must agree to use adequate contraception during MRG006A treatment and for 180 days after the last infusion.

排除标准:Exclusion Criteria:

  1. Prior histologically/cytologically confirmed diagnosis of hepatocellular carcinoma with fibrolamellar, sarcomatoid, cholangiocarcinoma, or other components.
  2. History of hepatic failure or hepatic encephalopathy, or history of liver transplantation.
  3. Pleural effusion, ascites, or pelvic effusion, or clinically significant pericardial effusion.
  4. Acute or chronic active hepatitis B or hepatitis C infection.
  5. Central nervous system metastases.
  6. Prior locoregional therapy for hepatocellular carcinoma within 4 weeks before first dose administration.
  7. Receipt of live attenuated vaccines within 4 weeks before first dose or planned administration during the study period.
  8. Major surgical procedure within 4 weeks before first dose, or the presence of unhealed wounds, ulcers, or bone fractures.
  9. Uncontrolled or poorly controlled medical conditions.
  10. Toxicities from prior therapy that have not resolved to Grade 0 or 1 before first dose of study treatment.
  11. Severe cardiac insufficiency or cerebrovascular events within 6 months prior, or occurrence of pulmonary embolism, deep vein thrombosis, gastrointestinal perforation and/or fistula, or intestinal obstruction.
  12. Patients with double or multiple primary malignancies.
  13. Hypersensitivity to any component or excipient of the investigational product.
  14. Active or poorly controlled severe infection.
  15. Any severe and/or uncontrolled systemic disease that, in the opinion of the investigator and sponsor, renders the patient unsuitable for participation in this study.

引自 ClinicalTrials.gov, NCT07479485, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07479485,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07479485